Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 1Neoplasms 1Cancer Pain 1Breakthrough Pain 1

Interventions

Fentanyl 7Morphine 2Ultracet 1Passive Cutaneous Anaphylaxis 1Methadone 1Infusions, Intravenous 1Gastrostomy 1Administration, Sublingual 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breakthrough Pain × Ultracet × Clear all
NCT00576173 2010-04-28

An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

Johnson & Johnson Taiwan Ltd

Phase 4 Completed
60 enrolled

Cancer Pain, Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡